Antibody Therapeutics
Total Trials
11
As Lead Sponsor
9
As Collaborator
2
Total Enrollment
485
NCT01221571
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 31, 2010
Completion: Jun 30, 2013
NCT02106091
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
Start: Apr 30, 2014
Completion: Sep 30, 2018
NCT02321592
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase 2
Role: Collaborator
Start: May 31, 2015
Completion: Jul 31, 2020
NCT02665650
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Start: May 31, 2016
Completion: Mar 31, 2019
NCT02848911
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
Start: Oct 31, 2016
Completion: Apr 30, 2019
NCT04101331
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Start: Nov 13, 2019
Completion: Jan 11, 2024
NCT04259450
Study to Assess AFM24 in Advanced Solid Cancers
Phase: Phase 1/2
Start: Apr 7, 2020
Completion: Jun 24, 2024
NCT05099549
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Start: Nov 3, 2021
Completion: Sep 21, 2023
NCT05109442
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Start: Nov 19, 2021
Completion: Jun 11, 2025
NCT05817058
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Start: Mar 21, 2023
Completion: Jun 13, 2025
NCT05883449
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Start: Oct 10, 2023
Loading map...